dNerva Lung Denervation System / Targeted Lung Denervation (TLD)
Chronic Obstructive Pulmonary Disease (COPD)
Phase 3Active
Key Facts
About Nuvaira
Nuvaira is a clinical-stage medical device company pioneering a novel, interventional approach to treating COPD. Its core technology, the dNerva System, delivers radiofrequency (RF) ablation to pulmonary nerves via bronchoscopy, aiming to create a durable 'always-on' bronchodilator effect. The company is advancing this therapy through a robust clinical development program, with data suggesting improvements in lung function, reduction in exacerbations, and decreased breathlessness for a targeted COPD patient population. Nuvaira operates as a private entity, positioning its one-time procedural therapy as a potential complement or alternative to lifelong inhaled medications.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease (COPD) Drugs
| Drug | Company | Phase |
|---|---|---|
| PUR0200 | Pulmatrix | Preclinical |
| Dupixent (dupilumab) | Regeneron | Phase 3 |
| REGEND001 | Regend | Phase 1 |
| COPD Trial | Well Pharma Medical Research | Not Specified |
| AN01 | AirNexis Therapeutics | Phase 2 |
| COPD Diagnostic/Prognostic Test | Oxford Cancer Analytics | Pre-clinical |
| SMS Cell Therapy | SMSbiotech | Phase 1b |
| LBP for COPD | Alveolus Bio | Preclinical |
| AstraZeneca Collaboration Programs | Ethris | Discovery/Pre-clinical |
| COPD Phenotyping & Progression Biomarkers | Thirona | Commercial/Validation |
| TEZSPIRE (tezepelumab) | Amgen | Phase 3 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |